NCT03661723 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03661723
Title	Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Dana-Farber Cancer Institute
Indications	glioblastoma
Therapies	Bevacizumab Pembrolizumab Bevacizumab + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA

Filter rows:

Showing 1 to 5 of 5 entries

Facility	City	State	Zip	Country	Details
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02115	United States	Details
Columbia University / Herbert Irving Comprehensive Cancer Center	New York	New York	10032	United States	Details
Dana Farber Cancer Institute	Boston	Massachusetts	02115	United States	Details
Hospital of the University of Pennsylvania, Abramson Cancer Center	Philadelphia	Pennsylvania	19104	United States	Details
Massachusetts General Hospital	Boston	Massachusetts	02214	United States	Details

Showing 1 to 5 of 5 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03661723Clinical Trial Detail